The cost-effectiveness of newborn screening for spinal muscular atrophy
- PMID: 35698880
- DOI: 10.1111/dmcn.15314
The cost-effectiveness of newborn screening for spinal muscular atrophy
Comment on
-
Financial cost and quality of life of patients with spinal muscular atrophy identified by symptoms or newborn screening.Dev Med Child Neurol. 2023 Jan;65(1):67-77. doi: 10.1111/dmcn.15286. Epub 2022 Jun 8. Dev Med Child Neurol. 2023. PMID: 35673937
References
REFERENCES
-
- Wilson JMG, Jungner G. Principles and practice of screening for disease. Geneva: World Health Organization, 1968.
-
- De Vivo DC, Bertini E, Swoboda KJ, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord 2019; 29: 842-56.
-
- Dangouloff T, Hiligsmann M, Deconinck N, et al. Financial cost and quality of life of patients with spinal muscular atrophy identified by symptoms or by newborn screening. Dev Med Child Neurol 2022. https://doi.org/10.1111/dmcn.15286
-
- Landfeldt E, Edström J, Sejersen T, et al. Quality of life of patients with spinal muscular atrophy: A systematic review. Eur J Paediatr Neurol 2019; 23: 347-56.
-
- Landfeldt E, Pechmann A, McMillan HJ, Lochmüller H, Sejersen T. Costs of Illness of Spinal Muscular Atrophy: A Systematic Review. Appl Health Econ Health Policy 2021; 19: 501-20.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
